Post-traumatic stress disorder may be persistent or worsening in patients with cancer up to 4 years after an initial diagnosis of the disorder, according to the results of a study.
Combined analysis of risk factors predicts long-term cardiovascular complications in childhood cancer survivors more accurately than single-factor assessments.
Women who take multivitamin supplements before their breast cancer diagnosis and during chemotherapy appear to be less likely to develop the debilitating, often long-lasting symptoms of chemotherapy-induced peripheral neuropathy, according to a new study.
The US Food and Drug Administration has approved the tyrosine kinase inhibitor ibrutinib (Imbruvica) for adult patients with chronic graft vs host disease who have failed on one or more lines of prior systemic therapy.
A combination of netupitant and palonosetron was non-inferior to aprepitant plus granisetron in preventing chemotherapy-induced nausea and vomiting.
Treatment with the gonadotropin-releasing hormone (GnRH) agonist goserelin can reduce the risk of chemotherapy-induced premature ovarian insufficiency (POI) in women with early breast cancer.
Blended cognitive behavior therapy can help reduce the severity of fear of cancer recurrence in survivors, according to a new randomized study.
Chlorhexidine wipe bathing might help reduce the risk of deadly central line-associated bloodstream infections (CLABSIs) among cancer inpatients, but barriers can complicate implementation efforts.
Nurse practitioners play a central role in helping patients with esophageal cancer understand and manage their disease and treatment complications.
Administration of dexrazoxane along with adjuvant chemotherapy was cardioprotective in patients with HER2-positive breast cancer treated with chemotherapy followed by 1 year of trastuzumab maintenance therapy.